Literature DB >> 12433366

Immunodominance of H60 is caused by an abnormally high precursor T cell pool directed against its unique minor histocompatibility antigen peptide.

Eun Young Choi1, Gregory J Christianson, Yoshitaka Yoshimura, Thomas J Sproule, Nadja Jung, Sebastian Joyce, Derry C Roopenian.   

Abstract

The H60 minor histocompatibility (H) antigen peptide is derived from a glycoprotein that serves as a ligand for the stimulatory NKG2D receptor. We show that this peptide is remarkably immunodominant in that it competes effectively with MHC alloantigens, is efficiently crosspresented by host antigen-presenting cells (APCs), and readily elicits naive CD8 T cell responses in vitro. H60 immunodominance is neither a consequence of NKG2D engagement nor competition among minor H antigens on APCs. Instead, H60 immunodominance is a consequence of an abnormally high naive precursor frequency of H60 peptide reactive CD8 T cells. Understanding why the H60 peptide is so immunogenic has important implications in tissue transplantation and vaccine design.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12433366     DOI: 10.1016/s1074-7613(02)00428-4

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  39 in total

1.  A single nucleotide polymorphism in the Emp3 gene defines the H4 minor histocompatibility antigen.

Authors:  Brianna Luedtke; Laura M Pooler; Eun Young Choi; Angela M Tranchita; Corbett J A Reinbold; Aaron C Brown; Daniel J Shaffer; Derry C Roopenian; Subramaniam Malarkannan
Journal:  Immunogenetics       Date:  2003-07-04       Impact factor: 2.846

Review 2.  Sizing up the key determinants of the CD8(+) T cell response.

Authors:  David C Tscharke; Nathan P Croft; Peter C Doherty; Nicole L La Gruta
Journal:  Nat Rev Immunol       Date:  2015-10-09       Impact factor: 53.106

3.  A virus-specific CD8+ T cell immunodominance hierarchy determined by antigen dose and precursor frequencies.

Authors:  Nicole L La Gruta; Katherine Kedzierska; Ken Pang; Richard Webby; Miles Davenport; Weisan Chen; Stephen J Turner; Peter C Doherty
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-17       Impact factor: 11.205

4.  Contribution of T-cell receptor repertoire breadth to the dominance of epitope-specific CD8+ T-lymphocyte responses.

Authors:  Edwin R Manuel; William A Charini; Pritha Sen; Fred W Peyerl; Marcelo J Kuroda; Jörn E Schmitz; Patrick Autissier; Dennis A Sheeter; Bruce E Torbett; Norman L Letvin
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

5.  Survival and function of MiHA epitope-specific host CD8 TM cells following ablative conditioning and HCT.

Authors:  Alwi M Shatry; Derry C Roopenian; Robert B Levy
Journal:  Biol Blood Marrow Transplant       Date:  2007-03       Impact factor: 5.742

6.  Recognition of allo-peptide is governed by novel anchor imposition and limited variations in TCR contact residues.

Authors:  Corbett J A Reinbold; Subramaniam Malarkannan
Journal:  Mol Immunol       Date:  2007-11-05       Impact factor: 4.407

7.  Epitope specificity delimits the functional capabilities of vaccine-induced CD8 T cell populations.

Authors:  Brenna J Hill; Patricia A Darrah; Zachary Ende; David R Ambrozak; Kylie M Quinn; Sam Darko; Emma Gostick; Linda Wooldridge; Hugo A van den Berg; Vanessa Venturi; Martin Larsen; Miles P Davenport; Robert A Seder; David A Price; Daniel C Douek
Journal:  J Immunol       Date:  2014-10-27       Impact factor: 5.422

8.  A single-amino-acid variant of the H60 CD8 epitope generates specific immunity with diverse TCR recruitment.

Authors:  Su Jeong Ryu; Ji Yeong Jeon; Jun Chang; Thomas J Sproule; Derry C Roopenian; Eun Young Choi
Journal:  Mol Cells       Date:  2012-03-21       Impact factor: 5.034

9.  Altered CD8(+) T cell immunodominance after vaccinia virus infection and the naive repertoire in inbred and F(1) mice.

Authors:  Inge E A Flesch; Wai-Ping Woo; Yang Wang; Vijay Panchanathan; Yik-Chun Wong; Nicole L La Gruta; Tania Cukalac; David C Tscharke
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

Review 10.  Acute graft-versus-host disease: from the bench to the bedside.

Authors:  Gerard Socié; Bruce R Blazar
Journal:  Blood       Date:  2009-08-27       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.